Publikationen von Roman K. Thomas
Alle Typen
Zeitschriftenartikel (72)
41.
Zeitschriftenartikel
4 (9), S. S800 - S800 (2009)
Chemical genomics of RAD001 in non-small cell lung cancer. Journal of Thoracic Oncology 42.
Zeitschriftenartikel
34 (2), S. 489 - 506 (2009)
High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications. European Respiratory Journal 43.
Zeitschriftenartikel
119 (6), S. 1727 - 1740 (2009)
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. Journal of Clinical Investigation 44.
Zeitschriftenartikel
69 (8), S. 3256 - 3261 (2009)
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Research 45.
Zeitschriftenartikel
25 (6), S. 722 - 728 (2009)
A flexible rank-based framework for detecting copy number aberrations from array data. Bioinformatics 46.
Zeitschriftenartikel
106 (12), S. 4834 - 4839 (2009)
Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proceedings of the National Academy of Sciences of the United States of America 47.
Zeitschriftenartikel
4 (10), S. e7273 - e7273 (2009)
High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-lGF-1R antibody (R1507). PLoS ONE 48.
Zeitschriftenartikel
50 (11), S. 1815 - 1819 (2009)
Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus. Journal of Nuclear Medicine 49.
Zeitschriftenartikel
3 (12), S. e3908 - e3908 (2008)
Early detection of erlotinib treatment response in NSCLC by 3'-Deoxy-3'-[18F]-fluoro-L-thymidine ([18F]FLT) positron emission tomography (PET). PLoS ONE 50.
Zeitschriftenartikel
9, S. Art.Nr. 475 (2008)
Standardized high-throughput evaluation of cell-based compound screens. BMC Bioinformatics 51.
Zeitschriftenartikel
455 (7216), S. 1069 - 1075 (2008)
Somatic mutations affect key pathways in lung adenocarcinoma. Nature 52.
Zeitschriftenartikel
68 (14), S. 5524 - 5528 (2008)
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Research 53.
Zeitschriftenartikel
14 (13), S. 4275 - 4283 (2008)
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clinical Cancer Research 54.
Zeitschriftenartikel
68 (14), S. 5827 - 5838 (2008)
Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Research 55.
Zeitschriftenartikel
68 (3), S. 664 - 673 (2008)
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Research 56.
Zeitschriftenartikel
3 (2), S. 170 - 173 (2008)
Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway. Journal of Thoracic Oncology 57.
Zeitschriftenartikel
450 (7171), S. 893 - 898 (2007)
Characterizing the cancer genome in lung adenocarcinoma. Nature 58.
Zeitschriftenartikel
104 (50), S. 20007 - 20012 (2007)
Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proceedings of the National Academy of Sciences of the United States of America 59.
Zeitschriftenartikel
2 (8), S. S381 - S382 (2007)
Translational lung cancer genomics. Journal of Thoracic Oncology 60.
Zeitschriftenartikel
26 (34), S. 5023 - 5027 (2007)
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ ERBB2 inhibitor HKI-272. Oncogene